IL1B and Alzheimer disease: However, the non-negligible safety profile of the currently available anti-IL1β drugs, their brain limited penetration and the multiple inflammatory signals downstream to NLRP3 inflammasome activation may limit their repurposing in the treatment of AD (Liang et al., 2022).